Adverse Event Reporting | Community Health

Adverse event reporting is a critical component of pharmacovigilance, the discipline that focuses on the identification, evaluation, and mitigation of adverse effects and other drug-related problems associated with pharmaceutical products. The process involves the systematic collection, assessment, and analysis of reports of adverse events, which are harmful and unintended responses to approved medicinal products, including lack of efficacy and medication errors. Effective adverse event reporting is essential for ensuring patient safety, improving public health, and promoting the responsible use of pharmaceutical products. According to the World Health Organization (WHO), adverse drug reactions (ADRs) are a significant cause of morbidity and mortality worldwide, with an estimated 10% of all hospital admissions attributed to ADRs. The European Union has expanded the definition of pharmacovigilance to include lack of efficacy and medication errors, recognizing that adverse outcomes extend beyond harmful responses to therapeutic failures and misuse. As of 2022, the FDA has received over 1.4 million adverse event reports, highlighting the need for robust reporting systems and rigorous analysis to identify safety signals and prevent harm to patients.